GlaxoSmithKline, Collegeville, PA 19426-0989, USA.
Eur J Cancer. 2011 Mar;47(5):697-701. doi: 10.1016/j.ejca.2010.12.023.
Response Evaluation Criteria in Solid Tumors (RECIST) is commonly used in oncology clinical trials and provides a standard approach for the assessment of treatment. However, data capture, validation and summarisation are complex. This article focuses on managing solid tumour lesion and response assessment data from capture through summarisation. Conventions for capturing lesion data, as well as considerations for data validation and summarisation, are provided. Recommendations are based on a review of data capture forms (including data items and instructions), data validation practices and algorithms for data summarisation across solid tumour studies at a single company. The intent of the authors is to share our experiences at GSK in the spirit of harmonisation by transparently describing our decisions and methods.
实体瘤反应评价标准(RECIST)常用于肿瘤学临床试验,为治疗评估提供了一种标准方法。然而,数据的采集、验证和总结非常复杂。本文重点关注从数据采集到总结的实体瘤病灶和反应评估数据的管理。本文提供了病灶数据采集的规范,以及数据验证和总结的注意事项。这些建议是基于对单个公司的实体瘤研究中数据采集表(包括数据项和说明)、数据验证实践以及数据总结算法的回顾。作者旨在通过透明地描述决策和方法,本着协调一致的精神,分享他们在葛兰素史克公司的经验。